As part of its manufacturing consolidation in the US, Mumbai-headquartered Sun Pharmaceuticals Industries, has agreed to divest two oral solid dosage manufacturing facilities in Philadelphia, Pennsylvania and Aurora, Illinois, along with 15 related pharmaceutical products to Frontida BioPharm, Inc.

In connection with the transaction, Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites. Further details were not disclosed.